Jiangsu Hengrui Pharmaceuticals Co.,Ltd (SHA:600276)
China · Delayed Price · Currency is CNY 56.77
-0.70 (-1.22%)
Feb 4, 2026, 1:25 PM CST
SHA:600276 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 28,008 | 25,010 | 22,377 | 21,213 | 25,780 | 27,613 |
Other Revenue | 2,975 | 2,975 | 442.6 | 62.25 | 125.22 | 121.91 |
| 30,983 | 27,985 | 22,820 | 21,275 | 25,906 | 27,735 | |
Revenue Growth (YoY) | 19.19% | 22.63% | 7.26% | -17.87% | -6.59% | 19.09% |
Cost of Revenue | 4,243 | 3,881 | 3,562 | 3,503 | 3,756 | 3,356 |
Gross Profit | 26,740 | 24,104 | 19,257 | 17,772 | 22,150 | 24,379 |
Selling, General & Admin | 11,816 | 10,892 | 9,994 | 9,654 | 12,244 | 12,869 |
Research & Development | 6,979 | 6,583 | 4,954 | 4,887 | 5,943 | 4,989 |
Other Operating Expenses | 154.46 | 182.17 | 149.03 | 145.32 | 201.81 | 239.35 |
Operating Expenses | 18,927 | 17,628 | 15,081 | 14,712 | 18,385 | 18,107 |
Operating Income | 7,813 | 6,476 | 4,176 | 3,060 | 3,765 | 6,272 |
Interest Expense | -14.6 | -5.56 | -5.9 | -6.49 | -4.71 | - |
Interest & Investment Income | 613.37 | 607.56 | 477.14 | 772.64 | 580.9 | 631.7 |
Currency Exchange Gain (Loss) | -24.04 | -24.04 | 7.9 | 93.19 | -22.42 | -101.97 |
Other Non Operating Income (Expenses) | 146.35 | -0.61 | 0.74 | -1.37 | -198.97 | -3.89 |
EBT Excluding Unusual Items | 8,535 | 7,053 | 4,656 | 3,918 | 4,119 | 6,798 |
Gain (Loss) on Sale of Investments | 187.5 | 108.63 | -107.41 | 76.5 | 36.23 | 16.5 |
Gain (Loss) on Sale of Assets | 2.76 | 5.4 | 3.16 | 4.23 | 1.64 | 2.98 |
Asset Writedown | -27.79 | -4.94 | -76.21 | -130 | - | -2.28 |
Other Unusual Items | -202.02 | 7.55 | 191.68 | 100.11 | 309.04 | 80.67 |
Pretax Income | 8,495 | 7,170 | 4,667 | 3,968 | 4,466 | 6,895 |
Income Tax Expense | 1,014 | 832.7 | 389.29 | 153.35 | -17.72 | 586.59 |
Earnings From Continuing Operations | 7,481 | 6,337 | 4,278 | 3,815 | 4,484 | 6,309 |
Minority Interest in Earnings | -12.78 | -0.47 | 24.62 | 91.23 | 46.19 | 19.49 |
Net Income | 7,468 | 6,337 | 4,302 | 3,906 | 4,530 | 6,328 |
Net Income to Common | 7,468 | 6,337 | 4,302 | 3,906 | 4,530 | 6,328 |
Net Income Growth | 37.07% | 47.28% | 10.14% | -13.77% | -28.41% | 18.77% |
Shares Outstanding (Basic) | 6,437 | 6,337 | 6,327 | 6,404 | 6,381 | 6,392 |
Shares Outstanding (Diluted) | 6,437 | 6,337 | 6,327 | 6,404 | 6,381 | 6,392 |
Shares Change (YoY) | 1.59% | 0.15% | -1.20% | 0.36% | -0.18% | -0.03% |
EPS (Basic) | 1.16 | 1.00 | 0.68 | 0.61 | 0.71 | 0.99 |
EPS (Diluted) | 1.16 | 1.00 | 0.68 | 0.61 | 0.71 | 0.99 |
EPS Growth | 34.93% | 47.06% | 11.47% | -14.09% | -28.28% | 18.80% |
Free Cash Flow | 9,789 | 5,454 | 6,160 | -726.91 | 2,554 | 2,878 |
Free Cash Flow Per Share | 1.52 | 0.86 | 0.97 | -0.11 | 0.40 | 0.45 |
Dividend Per Share | 0.200 | 0.200 | 0.200 | 0.160 | 0.160 | 0.167 |
Dividend Growth | - | - | 25.00% | - | -4.02% | 4.32% |
Gross Margin | 86.31% | 86.13% | 84.39% | 83.53% | 85.50% | 87.90% |
Operating Margin | 25.22% | 23.14% | 18.30% | 14.38% | 14.53% | 22.61% |
Profit Margin | 24.10% | 22.64% | 18.85% | 18.36% | 17.49% | 22.82% |
Free Cash Flow Margin | 31.59% | 19.49% | 26.99% | -3.42% | 9.86% | 10.38% |
EBITDA | 8,571 | 7,194 | 4,843 | 3,599 | 4,260 | 6,720 |
EBITDA Margin | 27.66% | 25.71% | 21.22% | 16.91% | 16.45% | 24.23% |
D&A For EBITDA | 757.41 | 718.46 | 666.52 | 539.12 | 495.59 | 448.39 |
EBIT | 7,813 | 6,476 | 4,176 | 3,060 | 3,765 | 6,272 |
EBIT Margin | 25.22% | 23.14% | 18.30% | 14.38% | 14.53% | 22.61% |
Effective Tax Rate | 11.94% | 11.61% | 8.34% | 3.86% | - | 8.51% |
Revenue as Reported | 30,983 | 27,985 | 22,820 | 21,275 | 25,906 | 27,735 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.